Onconetix, Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
Onconetix, Inc. (ONCO) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $655.44 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-03-13
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-06-30 was $345.32K.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-03-31 was -$30.78K.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-06-30 was -$33.41K.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-03-31 was -$154.68K.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was $655.44K.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was -$238.01K, a 4091.45% decline from fiscal 2023.
- Onconetix, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $5.96K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|
| 2025-12-31 | $655.44K 10-K · filed 2026-03-13 | ||
| 2025-06-30 | $345.32K 10-Q · filed 2025-08-14 | $314.54K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$30.78K 10-Q · filed 2025-06-12 | ||
| 2024-12-31 | -$238.01K 10-K · filed 2026-03-13 | ||
| 2024-06-30 | -$33.41K 10-Q · filed 2025-08-14 | $121.27K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | -$154.68K 10-Q · filed 2025-06-12 | ||
| 2023-12-31 | $5.96K 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |